KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Acadia Pharmaceuticals (ACAD) over the last 13 years, with Q3 2025 value amounting to $8.9 million.

  • Acadia Pharmaceuticals' Change in Receivables rose 23560.61% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year decrease of 1557.33%. This contributed to the annual value of $1.9 million for FY2024, which is 9480.76% down from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Change in Receivables of $8.9 million as of Q3 2025, which was up 23560.61% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Change in Receivables registered a high of $15.9 million during Q2 2023, and its lowest value of -$12.2 million during Q3 2022.
  • In the last 5 years, Acadia Pharmaceuticals' Change in Receivables had a median value of $5.2 million in 2022 and averaged $3.7 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first crashed by 35430.43% in 2021, then skyrocketed by 32504.54% in 2023.
  • Quarter analysis of 5 years shows Acadia Pharmaceuticals' Change in Receivables stood at $3.7 million in 2021, then skyrocketed by 76.08% to $6.5 million in 2022, then dropped by 15.43% to $5.5 million in 2023, then crashed by 213.41% to -$6.2 million in 2024, then skyrocketed by 242.95% to $8.9 million in 2025.
  • Its last three reported values are $8.9 million in Q3 2025, $1.8 million for Q2 2025, and $7.0 million during Q1 2025.